CHRISTOPHER WOODARD

Staff Reporter

Faced with slowing sales of its two primary products, Amgen Inc., the Thousand Oaks-based biotech company, has intensified its search for super-profitable drugs....

Subscribe to get the full story.


Are you a subscriber? Sign In